New research conducted by Rutgers University has successfully used cutting-edge technology to spot minuscule, hard-to-detect cancerous tumors. The scientists hope that they will be able to successfully use this technique in humans in the near future.
Moreover, the Centers for Disease Control and Prevention (CDC) have reported that cancer has become the leading cause of death in a rising number of U.S. states. In 2014,
At present, the most common means of
Now, researchers from Rutgers University in New Brunswick, NJ, have uncovered a way of spotting even the smallest of cancer tumors — which might, in the future, allow practitioners to effectively track when and where the cancer is spreading, enabling them to intervene sooner.
Prof. Prabhas V. Moghe and colleagues have started testing the use of light-emitting nanoparticles in the detection of cancerous cells. The
"We've always had this dream that we can track the progression of cancer in real time, and that's what we've done here. We've tracked the disease in its very incipient stages," says Prof. Moghe.
'Now we know the address of the cancer'
For the purpose of the research, the team worked with a mouse model of human breast cancer, injecting the animals with
The nanoprobes are carried along by the bloodstream, allowing the researchers to get a quick and reliable image of the location of affected cells in the body.
They explain that these nanoprobes worked faster than the MRI method when it came to identifying micrometastases in the bones and adrenal, or suprarenal, glands of the animals. This new method, the scientists suggest, may allow physicians to spot the spread of cancer much earlier in human patients.
"Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go," says study co-author Vidya Ganapathy. "You can treat the tumors intelligently because now you know the address of the cancer."
Prof. Moghe asserts that nanoparticles could successfully detect more than 100 different types of cancer. This cutting-edge method, he says, could be used to screen cancer in humans within 5 years.
Should this projection prove true, the use of nanoparticles might allow healthcare professionals to detect the spread of cancer cells early on, and to more accurately monitor whether or not cancer treatment has been fully successful.
"You can potentially determine the stage of the cancer and then figure out what's the right approach for a particular patient," says Prof. Moghe.
Another potential use of nanoprobes, the researchers note, could be to mark any tissue due to be removed during a surgery, as well as to test how effective immunotherapy, or the practice of boosting immune system reactions against cancer cells, is in the treatment of cancer.
"The Achilles' heel of surgical management for cancer is the presence of micrometastases. This is also a problem for proper staging or treatment planning. The nanoprobes described in this paper will go a long way to solving these problems."
Dr. Steven K. Libutti, director of the Rutgers Cancer Institute of New Jersey